206 related articles for article (PubMed ID: 26040548)
1. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A
Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548
[TBL] [Abstract][Full Text] [Related]
2. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
3. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Almholt K; Lund LR; Rygaard J; Nielsen BS; Danø K; Rømer J; Johnsen M
Int J Cancer; 2005 Feb; 113(4):525-32. PubMed ID: 15472905
[TBL] [Abstract][Full Text] [Related]
4. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
5. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
6. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
7. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
[TBL] [Abstract][Full Text] [Related]
8. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
9. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
Hemsen A; Riethdorf L; Brünner N; Berger J; Ebel S; Thomssen C; Jänicke F; Pantel K
Int J Cancer; 2003 Dec; 107(6):903-9. PubMed ID: 14601049
[TBL] [Abstract][Full Text] [Related]
11. [Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma].
Wang D; Wang T
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(12):529-31. PubMed ID: 16176001
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
14. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
17. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
[TBL] [Abstract][Full Text] [Related]
19. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
